Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1961 1
1964 1
1970 1
1971 1
1972 1
1973 1
1974 2
1975 1
1976 1
1977 2
1978 1
1980 1
1981 3
1982 1
1983 2
1984 1
1985 2
1986 1
1987 1
1988 1
1989 3
1990 3
1991 9
1992 6
1993 7
1994 7
1995 6
1996 12
1997 8
1998 5
1999 4
2000 7
2001 5
2002 1
2003 13
2004 3
2005 9
2006 13
2007 20
2008 26
2009 22
2010 31
2011 22
2012 34
2013 35
2014 29
2015 37
2016 38
2017 30
2018 34
2019 20
2020 17
2021 21
2022 21
2023 15
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

527 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Richter's syndrome.
Thompson PA, Siddiqi T. Thompson PA, et al. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):329-336. doi: 10.1182/hematology.2022000345. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485138 Free PMC article. Review.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR. Davids MS, et al. Among authors: thompson pa. Blood. 2022 Feb 3;139(5):686-689. doi: 10.1182/blood.2021011386. Blood. 2022. PMID: 34788401 Free PMC article. Clinical Trial.
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Guièze R, et al. Among authors: thompson pa. Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19. Cancer Cell. 2019. PMID: 31543463 Free PMC article.
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Among authors: thompson pa. Lancet Haematol. 2022 Dec;9(12):e878-e885. doi: 10.1016/S2352-3026(22)00285-X. Epub 2022 Oct 22. Lancet Haematol. 2022. PMID: 36279879 Clinical Trial.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Rogers KA, et al. Among authors: thompson pa. Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500. Haematologica. 2021. PMID: 33730844 Free PMC article. Clinical Trial.
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC; CRISP Consortium. Rossetti S, et al. Among authors: thompson pa. J Am Soc Nephrol. 2007 Jul;18(7):2143-60. doi: 10.1681/ASN.2006121387. Epub 2007 Jun 20. J Am Soc Nephrol. 2007. PMID: 17582161
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. DiNardo CD, et al. Among authors: thompson pa. Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
527 results